The Optos team constantly strives to improve upon our retinal imaging technology. In our effort to be THE retina company, we realize our technology is not only saving vision, it is also saving lives.

Denise Kniefel, OD knows the value of the optomap® exam because she has been a customer of Optos since 2004. No stranger to the technology, Dr. Kniefel started imaging her retina as a matter of course. In 2008 at a tradeshow, she stopped in to talk to the representatives from the company. Optos had recently unveiled new technology that allowed for even better optomap imaging than in the past. Dr. Kniefel sat down and had her retinal image captured. A nevus was detected that she hadn’t previously seen.

The image prompted Dr. Kniefel to see her ophthalmologist and have a fluorescein angiography and an OCT exam done. She did indeed have a nevus, which is essentially a freckle in the eye, and needs to be routinely monitored. Just like a freckle on your skin, it can change and become cancerous. Her doctor told her if the nevus did change into cancerous melanoma of eye, she would notice changes to her vision.

Denise continued to image herself every six months using the optomap, and in 2013, she noticed that the nevus looked different but she was not experiencing any vision loss. She went back to her retinal specialist who told her the nevus was now presenting as a very small choroidal melanoma. Dr. Kniefel went to Evangelos Gragoudas, MD at Massachusetts Eye and Ear Infirmary in December of 2013 for proton beam radiation. Because it is so soon after her treatment, her prognosis is unclear. However, because of the optomap technology, the cancer was caught at an extremely early stage, the best case scenario for a positive outcome.

Visit Optos today to learn more about our technology and to learn how partnering with us can help you See More. Treat More Effectively™.